• Aucun résultat trouvé

Adverse Events from Clinical Studies in Pharmaceutical Research and Development

N/A
N/A
Protected

Academic year: 2022

Partager "Adverse Events from Clinical Studies in Pharmaceutical Research and Development"

Copied!
2
0
0

Texte intégral

(1)

!"#$%&$'(#$)*&'+%,-'./0)012/'3*4"0$&'0)' 562%-21$4*012/'7$&$2%16'2)"'8$#$/,9-$)*'

!"#$%&"'(()*+$,-.(/"*$0).(1-.2$

3(/.#4-*-5#$678+$9:'*;#'+$<=-;-*$

!:&*%21*;'3$ (/#/-&-*/$ )>$ "*/-.-(/$ /)$ ?#./"5"?#/-$ "*$ /@-$ =).A(@)?$ 6-?.-(-*/"*2$ 3;B-.(-$

%B-*/(+$ #..#*2-;$ /)2-/@-.$ ="/@$ /@-$ C*/-.*#/")*#'$ D)*>-.-*5-$ )*$ E")&-;"5#'$ F*/)')2G$

HCDEFI+$ JK'G$ LMNNO$C*/.);K5"*2$ /@-$ 1K("*-(($ *--;($"*$ @#*;'"*2$ (#>-/G$"((K-($ #*;$ .-2K'#.$

)*2)"*2$?@#.&#5)B"2"'#*5-$"*$?@#.&#5-K/"5#'$.-(-#.5@$#*;$;-B-')?&-*/O$3*$)K/'"*-$)>$/@-$

?.)?)(-;$()'K/")*$#*;$/=)$-P#&?'-($)>$;">>-.-*/$#;B-.(-$-B-*/$5#(-($#($#$1#5A2.)K*;$/)$/@-$

#K/@).($="(@-($/)$K*;-.(/#*;$#$&).-$)*/)')2"5#'$#??.)#5@O$

<'' =4&0)$&&'>$$"'

678$#*;$/@-$!#/"-*/$<#>-/G$;-?#./&-*/$@#B-$

#$(/.#/-2"5$>)5K($/)$;-B-')?$?.-;"5/"B-$=#G($/)$

@#*;'-$ (#>-/G$ "((K-($ #*;$ .-2K'#.$ )*2)"*2$

?@#.&#5)B"2"'#*5-O$ Q@#/$ "(+$ /@-$ ;-/-5/")*+$

#((-((&-*/+$ K*;-.(/#*;"*2$ #*;$ ?.-B-*/")*$ )>$

#;B-.(-$ ->>-5/(+$ ?#./"5K'#.'G$ ')*2$ /-.&$ #*;$

(@)./$ /-.&$ (";-$ ->>-5/($ )>$ &-;"5"*-(O$

6-2K'#/).G$ #K/@)."/"-($ .-RK".-$ =-''$ ;-("2*-;$

#*;$?.)#5/"B-$."(A$&#*#2-&-*/$?'#*($/)$1-$"*$

?'#5-$ >.)&$ '#K*5@$ /@.)K2@)K/$ /@-$ =@)'-$

'">-5G5'-$ )>$ #$ ?.);K5/O$ Q@-$ *-=$ CS8$

HC*B-(/"2#/")*#'$ S-=$ 8.K2I$ .-2K'#/")*$ >.)&$

083+$ >).$ .)K/"*-$ .-B"-=$ )>$ "*5";-*5-$ .#/-($ )>$

#''$ (-.")K($ #*;$ *)*T(-.")K($ #;B-.(-$ -B-*/($ "*$

#''$5'"*"5#'$?.)2.#&(O$

9#*G$ 5'"*"5#'$ (/K;G$ ?.)2.#&($ .K*$

(-B-.#'$(/K;"-($=).';=";-$"*$?#.#''-'+$=@"5@$

5)K';$ .-(K'/$ "*$ #$ @"2@$ =).';=";-$ -P?)(K.-U$

@-*5-$ "/$ "($ -P/.-&-'G$ "&?)./#*/$ /)$ @#B-$

5)*/"*K)K($ #55-(($ /)$ )*2)"*2$ 5'"*"5#'$ (/K;G$

;#/#O$ Q)$ (K55-((>K''G$ @#*;'-$ )*2)"*2$

?@#.&#5)B"2"'#*5-$ #$ ?.-.-RK"("/-$ "($ #55-(($ /)$

5)*/"*K)K($.-'-B#*/$?))'-;$5'"*"5#'$(/K;G$;#/#$

"*$ #$ >).&#/$ /@#/$ &#A-$ "/$ ?)(("1'-$ /)$ .-B"-=+$

(-#.5@$ #*;$ #*(=-.$ RK-(/")*($ "*$ #$ B-.G$ (@)./$

/"&-$ >.#&-O$ Q@"($ .-RK".-($ 5)*("(/-*/$ 5);"*2+$

?.-T?.-?#.-;$ ?))'($ #*;$ ;-."B-;$ B#."#1'-(O$

0K./@-.&).-+$/@-$.-(K'/$)>$/@-$(-#.5@-($"*$/@-$

?))'-;$ 5'"*"5#'$ (/K;G$ ;#/#$ (@)K';$ 1-$ ?K/$ "*$

5)*/-P/$ )>$ )/@-.$ .-(K'/($ 1)/@$ "*(";-$ #*;$

)K/(";-$ /@-$ ?@#.&$ 5)&?#*GO$ C*$ #;;"/")*$ "/$ "($

.-RK".-;$ /)$ A--?$ /.#5A$ )>$ -#5@$ ("*2'-$ ;#/#$

?)"*/$ /@.)K2@$ /@-$ ;#/#$ 5)''-5/")*$ #*;$

.->"*-&-*/$ 5@#"*$ #($ /@"($ 5)*/."1K/-($ /)$ /@-$

>"*#'$.-(K'/O$$

Q@-$)B-.#''$1K("*-(($?.)1'-&$#($(/#/-;$>).$

/@-$)*2)"*2$3(/.#4-*-5#$?.)V-5/$5#''-;$WK-(/X$

S)$ 2')1#'$ #K/)&#/"5$ =#G$ /)$ #55-((+$ (/.K5/K.-$

#*;$#*#'GY-$(#>-/G$.-'#/-;$5'"*"5#'$(/K;G$;#/#$

H"*5'K;"*2$ )*2)"*2$ (/K;G$ ;#/#I$ #/$ ;.K2$

?.);K5/Z?.)V-5/$'-B-'O$

E-')=$ #*$ )K/'"*-$ )>$ /@-$ ?.)?)(-;$ ()'K/")*$

>).$.-?.-(-*/#/")*$)>$#;B-.(-$-B-*/($"*>'K-*5-($

1G$ -P"(/"*2$ (/#*;#.;($ >)5K(-;$ )*$ ;#/#$

-P5@#*2-$ #*;$ 5);"*2O$ Q@"($ )B-.B"-=$ #*;$ /=)$

-P#&?'-($)>$5#(-($?.)B";-$()&-$1#5A2.)K*;$/)$

)K.$ "*/-.-(/$ "*$ 1-//-.$ K*;-.(/#*;"*2$ #$ &).-$

)*/)')2"5#'$ #??.)#5@$ /)$ .-?.-(-*/$ #;B-.(-$

-B-*/($ "*$ /@-$ 5)*/-P/$ )>$ ?@#.&#5-K/"5#'$

.-(-#.5@$ #*;$ ;-B-')?&-*/O$ [-$ #'()$ -P?').-$

(-&#*/"5$ =-1$ (/#*;#.;($ #*;$ '"*A-;$ ;#/#$

?."*5"?'-($ /)$ "&?.)B-$ /@-$ .-(-#.5@$ K/"'"/G$ )>$

;#/#$"*$5'"*"5#'$(/K;"-(O$

?'' 3,/4*0,)'@#$%#0$A'

3$ (#>-/G$ #*#'G("($ -*B".)*&-*/$ @#($ 1--*$

?.)?)(-;$ 1G$ /@-$ WK-(/$ ?.)V-5/O$ C/$ "*5'K;-(X$

D'"*"5#'$ (/K;G$ ;#/#$ H'-2#5G+$ 5)&?'-/-;+$

)*2)"*2I+$ </.K5/K.-$ H)?/"&"Y-;$ >).$ !#/"-*/$

<#>-/G$ RK-."-(I+$ 3*#'GY-$ ²$ H;-(5."?/"B-$

(/#/"(/"5($ #*;$ 2.#?@"5#'$ )K/?K/I+$ !.)5-((-($

H@)=$/)$=).A$K("*2$/@-(-$*-=$)?/")*(IO$

3$ .-'#/")*#'$ ;#/#1#(-$ ;-("2*+$ 1K"';"*2$ )*$

/@-$ -P?-."-*5-($ )>$ /=)$ '#.2-$ 3;B-.(-$ %B-*/($

;#/#1#(-($ "*$ ?.);K5/")*$ >).$ #??.)P"&#/-$ LM$

G-#.($ @#B-$ 1--*$ ?.)?)(-;$ >).$ /@-$ 5-*/.#'$

WK-(/$;#/#1#(-O$

$$

,&%2,QWHUQDWLRQDO&RQIHUHQFHRQ%LRPHGLFDO2QWRORJ\ā%XIIDOR1<86$

5HSUHVHQWLQJ$GYHUVH(YHQWV:RUNVKRS-XO\

(2)

!"#$%&'()!"#$%$&'(!)*'&+!&$,*+-$.!

!" #$%" &'(&$)*" +(" *,$" -$.+/(" '0" *,$" 12$.*"

-3*343.$" +." )$5+'-." $6/6" 52(7+(8" '(" *5$3*9$(*8"

:3.,7'2*8"0';;':72)"3(-"*,$".$<2$(&$"'0"*,$.$"

)$5+'-.6"=,$")$5+'-.":+;;"3;.'"5$0;$&*"*,$",3;07

;+0$" '0" *,$" -52/" .*2-+$-6" !;;" 0+(-+(/.8" $>$(*."

3(-" +(*$5>$(*+'(."($$-" *'" 4$" ;+(#$-" *'" '($"'5"

.$>$53;")$5+'-.6""

=,+." +." 3;.'" 3(" $?39);$" '0" ,':" $?+.*+(/"

-3*3" $?&,3(/$" .*3(-35-." ,3>$" +(0;2$(&$-" *,$"

9+(-.$*" +(" ),3593&$2*+&3;" 5$.$35&," 3(-"

-$>$;')9$(*"'(",':"3->$5.$"$>$(*.".,'2;-"4$"

5$)5$.$(*$-6" @(" *,+." &3.$" +*" +." *,$" /$($53;"

FODVVLILFDWLRQ RI ´REVHUYDWLRQVµ LH GDWD

$?&,3(/$"5$&'5-.8"+("*$59."'0""0+(-+(/.8"$>$(*."

3(-" +(*$5>$(*+'(." 3&&'5-+(/" *'" AB@6&·V CA;+(+&3;" B3*3" @(*$5&,3(/$" D*3(-35-."

A'(.'5*+29E" .*3(-35-" &3;;$-" DB=F" CD*2-%"

B3*3" =342;3*+'(" F'-$;E6" !('*,$5" $?39);$" +."

DB=F" .*3(-35-" 0'5" -3*3" .*52&*25$." 3(-"

$;$9$(*.8" $6/6" *,$" $?*$(-$-" !G" -'93+(" 0'5"

.30$*%" 3(3;%.+.6" ='/$*,$5" :+*," AB@DA·V

&'(*5';;$-"*$59+(';'/%":+*,";+.*."'0"&'-$."C*$?*"

.*5+(/." *'" 4$" 2.$-" 3." .249+..+'(" >3;2$.E" 0'5"

.30$*%" 3(3;%.+." .2&," 3." *,$" D$>$5+*%H@(*$(.+*%"

D&3;$" 0'5" !->$5.$" G>$(*.8" :+*," *$?*" .*5+(/.I"

´0,/'µ´02'(5$7(µ´6(9(5(µ"

=,$" -+&*+'(35%" 0'5" &'-+(/" '0" $?);+&+*" !G"

5$&'5-." +(" &;+(+&3;" *5+3;." .)'(.'5$-" 4%"

),3593&$2*+&3;" &'9)3(+$." +." F$-BJ!6"

!->$5.$" $>$(*." &3(" 3;.'" 4$" *,$" +9);+$-"

&'(.$<2$(&$" '0" 3" &'94+(3*+'(" '0" 9$3.25$7 9$(*.6" K$;':" *:'" $?39);$." +..2$." :,$(" +*"

&'9$."*'">$5.+'(+(/"'0"F$-BJ!"*$59."3(-"3("

$?39);$"'0"3";34"9$3.25$9$(*"43.$-"3->$5.$"

$>$(*"&3.$6"

!""#$%&'%

!" 93+(" +..2$" +." *,$" 2.$" '0" -+00$5$(*" F$-BJ!"

>$5.+'(." :+*," )'*$(*+3;;%" ($:" .'" &3;;$-"

)5$0$55$-" *$59." CL=I.E" 3(-" ($:" ,+$535&,+$.6"

M':$>$5" ('" ;':" ;$>$;" *$59." CNN=E" 35$"

-$;$*$-H5$2.$-6"""

*%"#"+,-'./0&0' 1&0234'556'

*%"#"+,-'./0&0'

1&0234'76' .$%%&+8'1&0234'76'

/'01-.'&&!$2!3'0(! /'0(043'! /'0(!(-&4$52$#+!

/'0(043'!10&$5$+$#! /'0(043'! 6,*&+'#!3'0(043'!

/'0(043'!7.-,0+'#0,! /'0(043'! /'5-4'%30,0,8-0!

!"#$%&'9)!9:05%,'!$2!;'(<=>!+'#5&!0.(!1'#&-$.&!

!""#$%&(%

!->$5.$"$>$(*."&3("3;.'"4$"*,$"&'(.$<2$(&$"'0"

3"&'94+(3*+'("'0"9$3.25$9$(*.6"O'5"$?39);$"

)'$·VGRFXPHQW´*XLGDQFHIRU,QGXVWU\'UXJ7

@(-2&$-" N+>$5" @(P25%I" L5$935#$*+(/" A;+(+&3;"

(YDOXDWLRQµIURP-XO\GHVFULEHVWKH+\V N3:"CLMNE6"

xWŽƚĞŶƚŝĂů,LJ͛Ɛ>Ăǁ;W,>ͿĐĂƐĞŝƐĚĞĨŝŶĞĚĂƐĂŶLJƐŝƚƵĂƚŝŽŶ

?3'#'!0!&+*(@!&*AB'4+!

!

x/0&!0.!-.4#'0&'!-.!A$+3!0,0.-.'!$#!0&%0#+0+'!

ĂŵŝŶŽƚƌĂŶƐĨĞƌĂƐĞ;>dŽƌ^dͿшϯdžh>EĂŶĚƚŽƚĂů ďŝůŝƌƵďŝŶ;d>ͿшϮdžh>E!

!

xC##'&%'4+-1'!$2!0,D0,-.'!%3$&%30+0&'!E>F"GH!0+!0.@!%$-.+!

(*#-.8!+3'!&+*(@!

!

xI3'!','10+-$.&!($!.$+!301'!+$!$44*#!0+!+3'!&05'!+-5'!$#!

?-+3-.!0!&%'4-2-'(!+-5'!2#05'!

Références

Documents relatifs

In this paper, we introduce the basic framework of the OVAE and how OVAE is used to represent and analyze all adverse events reported in the product package inserts

MedDRA - the Medical Dictionary for Regulatory Activities - is currently being used to encode adverse events reports into reporting systems such as the

[r]

A data science approach to drug safety: Semantic and visual mining of adverse drug events from clinical trials of pain treatments... A data science approach to

Key findings are: (1) Health care providers involved in adverse events need to be given the opportunity to talk about their experience; (2) The best way to provide support is

A robust method to explore the formation and interaction histories of nearby galaxies, where individual stars can be resolved (such as the Magellanic Clouds), entails the study of

(1996b) has the same distribution of source properties as any sample that we might define for the purposes of these observations. Such newly identified submilli-

Adverse effects in wild fish living downstream from pharmaceutical manufacture discharges... Institut National de l’Environnement Industriel et des Risques